At this point is it safe to assume GILD's Sofosbuvir does not have the risks associated with similar nucs like that from INHX/BMS? Will the safety factor be a concern for some physicians especially if the regimens are longer than 12 weeks? I wonder if there is whether it could lead some physicians to ABBV/ENTA regimen.